Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 1775 of 2051 entries
View as:

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)

Phase: N/A Priority: Normal
NCT ID: NCT03221426 Org: User:
Start: 10/09/17 End: 04/23/25 Due: 04/23/26

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study

Phase: N/A Priority: Normal
NCT ID: NCT05600309 Org: User:
Start: 06/14/22 End: 02/21/25 Due: 02/21/26

Safety, Tolerability, and Immunogenicity of a Booster Dose of Zoster Vaccine, Live (V211-029)

Phase: N/A Priority: Normal
NCT ID: NCT01245751 Org: User:
Start: 04/30/11 End: 05/31/15 Due: 05/31/16

Bioequivalence of Two Formulations of Ondansetron in Healthy Adults (0869-106)

Phase: N/A Priority: Normal
NCT ID: NCT00972595 Org: User:
Start: 06/30/04 End: 09/30/04 Due: 09/30/05

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension

Phase: N/A Priority: Normal
NCT ID: NCT04882241 Org: User:
Start: 07/29/20 End: 04/23/25 Due: 04/23/26

Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042)

Phase: N/A Priority: Normal
NCT ID: NCT01841684 Org: User:
Start: 06/30/13 End: 06/30/14 Due: 06/30/15

Comparison of Rocuronium and Org 25969 With Cisatracurium and Neostigmine (19.4.310)(P05931)

Phase: N/A Priority: Normal
NCT ID: NCT00451100 Org: User:
Start: 11/10/05 End: 08/29/06 Due: 08/29/07

A Study to Evaluate the Safety and Immunogenicity of V710 in Adults With Kidney Disease on Hemodialysis (V710-005)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00572910 Org: User:
Start: 08/31/08 End: 01/31/10 Due: 01/31/11

A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Participants With Impaired Renal Function (MK-7655-005)

Phase: N/A Priority: Normal
NCT ID: NCT01275170 Org: User:
Start: 01/28/11 End: 03/05/12 Due: 03/05/13

Long-Term Effects of Infliximab in the Treatment of Moderate to Severe Psoriasis [Extension of Study P04271, NCT00251641] (P04563)

Phase: N/A Priority: Normal
NCT ID: NCT00358670 Org: User:
Start: 05/31/06 End: 01/31/09 Due: 01/31/10

Efficacy and Safety Trial to Evaluate the Effect of SCH 497079 on Weight in Obese and Overweight Participants (Study P05483)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00642993 Org: User:
Start: 06/09/08 End: 01/30/09 Due: 01/30/10

Cognition Platform Study in Participants at Risk for Alzheimer's Disease (AD) (MK-0000-413)

Phase: N/A Priority: Normal
NCT ID: NCT04730635 Org: User:
Start: 03/23/21 End: 02/06/23 Due: 02/06/24

Study of Safety and Pharmacokinetics of MK-8242 in Participants With Advanced Solid Tumors (P07650)

Phase: N/A Priority: Normal
NCT ID: NCT01463696 Org: User:
Start: 12/21/11 End: 10/15/15 Due: 10/15/16

A Study of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutations (MK-8669-021 AM1)

Phase: N/A Priority: Normal
NCT ID: NCT00818675 Org: User:
Start: 03/31/09 End: 08/31/12 Due: 08/31/13

A Study to Assess the Effects of Exenatide on Insulin Secretion Rates Using a Graded Infusion of Intravenous Glucose (0000-099)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT01021527 Org: User:
Start: 02/29/08 End: 04/30/08 Due: 04/30/09

Pharmacoeconomic Study Assessing the Cost of Chronic Hepatitis C Treatment With Peginterferon Alfa-2b (PegIntron) and Ribavirin (Rebetol) in the Czech Republic (Study P04588)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00723632 Org: User:
Start: 09/30/05 End: 12/31/10 Due: 12/31/11

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension

Phase: N/A Priority: Normal
NCT ID: NCT05523323 Org: User:
Start: 10/30/20 End: 03/28/25 Due: 03/28/26

A Study of the Pharmacokinetics of Uprifosbuvir (MK-3682) and Ruzasvir (MK-8408) in Participants With Moderate and Severe Hepatic Insufficiency (MK-3682-029)

Phase: N/A Priority: Normal
NCT ID: NCT02666352 Org: User:
Start: 01/22/16 End: 01/16/17 Due: 01/16/18

Three Regimens of PegIntron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548)

Phase: N/A Priority: Normal
NCT ID: NCT00302081 Org: User:
Start: 08/31/03 End: 04/30/08 Due: 04/30/09

A Study of Different Doses of Sitagliptin (MK-0431) in Participants With Type 2 Diabetes Mellitus (MK-0431-014)

Phase: N/A Priority: Normal
NCT ID: NCT00481663 Org: User:
Start: 08/19/03 End: 05/14/06 Due: 05/14/07

Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

Phase: N/A Priority: Normal
NCT ID: NCT04123366 Org: User:
Start: 11/18/19 End: 07/23/26 Due: 07/23/27

Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002)

Phase: N/A Priority: Normal
NCT ID: NCT00851643 Org: User:
Start: 04/30/06 End: 11/30/09 Due: 11/30/10

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00034983 Org: User:
Start: 10/29/01 End: 12/29/03 Due: 12/29/04

Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100)

Phase: N/A Priority: Normal
NCT ID: NCT02674061 Org: User:
Start: 02/25/16 End: 03/18/21 Due: 03/18/22

Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2)

Phase: N/A Priority: Normal
NCT ID: NCT00723827 Org: User:
Start: 03/31/08 End: 09/30/11 Due: 09/30/12